<p>马萨诸塞州剑桥市 --（商业资讯）--Enveric Biosciences, Inc.（纳斯达克：ENVB）（“Enveric” 或 “公司”）是一家生物技术公司，致力于开发下一代神经可塑性小分子，以应对精神和神经疾病。今天，公司宣布已完成之前宣布的行使某些未到期认股权证的交易，购买总计 426,390 股，最初于 2025 年 2 月和 2025 年 9 月发行，行使价格分别为每股 36.00 美元和 10.98 美元，现以每股 7.05 美元的降低行使价格进行行使。根据有效的 S-1 表格（编号 333-284277）和 S-3 表格（编号 333-290580）注册声明，行使认股权证后可发行的普通股已注册。公司从行使认股权证中获得的总收益约为 310 万美元，未扣除承销商费用和预计的发行费用。</p>
<p>H.C. Wainwright &amp; Co. 担任此次发行的独家承销商。</p>
<p>作为立即以现金行使认股权证的对价，并支付每个新未注册认股权证额外 0.125 美元（总计 106,597.50 美元，已包含在公司总收益中），公司发行了新的未注册 E 系列认股权证，购买最多 426,390 股普通股，以及新的未注册 F 系列认股权证，购买最多 426,390 股普通股。新的 E 系列认股权证的行使价格为每股 7.05 美元，可立即行使，并将在转售注册声明生效后五年到期。新的 F 系列认股权证的行使价格为每股 7.05 美元，可立即行使，并将在转售注册声明生效后十八个月到期。</p>
<p>公司计划将此次发行的净收益用于产品开发、营运资金和一般企业用途。</p>
<p>上述新认股权证是在适用的证券法 1933 年修正案（“1933 年法”）的注册要求豁免下进行的私募发行，并且与行使后可发行的普通股一起，尚未根据 1933 年法进行注册，且在未向证券交易委员会（“SEC”）注册或获得适用的豁免之前，不能在美国进行要约或销售。公司已同意向 SEC 提交一份注册声明，涵盖行使新认股权证后可发行的普通股的转售（“转售注册声明”）。</p>
<p>本新闻稿不构成出售或招揽购买此处描述的任何证券的要约，也不应在任何州或其他司法管辖区进行这些证券的销售，除非在任何此类州或其他司法管辖区的证券法下进行注册或资格认证。</p>
<p><strong>关于 Enveric Biosciences</strong></p>
<p>Enveric Biosciences（纳斯达克：ENVB）是一家生物技术公司，专注于开发下一代小分子神经可塑性治疗药物，以满足精神和神经疾病的未满足需求。通过利用差异化的药物发现平台和不断增长的专利保护化学结构库，Enveric 正在推进一系列新型化合物的研发，旨在促进神经可塑性而不产生迷幻效果。Enveric 的主要候选药物 EB-003 是首个已知的化合物，旨在选择性地作用于 5-HT₂A 和 5-HT₁B 受体，具有快速、持久的抗抑郁和抗焦虑效果，并便于门诊使用。</p>
<p>欲了解更多信息，请访问 www.enveric.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含适用证券法意义上的前瞻性陈述和前瞻性信息。这些陈述涉及未来事件或未来表现。除历史事实陈述外的所有陈述均可能是前瞻性陈述或信息。通常，前瞻性陈述和信息可以通过使用前瞻性术语来识别，例如 “计划”、“预期” 或 “未预期”、“提议”、“预算”、“探索”、“安排”、“寻求”、“估计”、“预测”、“打算”、“预期” 或 “未预期”，或 “相信”，或这些词语和短语的变体，或通过使用表明某些行动、事件或结果可能、能够、应该、会或可能发生或实现的词语或短语。前瞻性陈述可能包括关于未来的信念、计划、期望或意图的陈述，并基于管理层的信念以及管理层所做的假设和当前可用的信息，包括但不限于关于预期使用发行收益的陈述。实际结果可能因某些因素而与前瞻性陈述所设想的结果有重大差异，包括但不限于，Enveric 能否：最终确定并提交其 IND 申请给美国食品药品监督管理局；成功开展临床项目；实现技术发展所设想的价值创造；避免计划临床试验的延误；在临床前或临床试验中证明潜在产品的有效性或安全性；建立或维持治疗候选药物开发的合作关系；获得适当或必要的政府批准以市场潜在产品；以商业合理的条款获得未来产品开发和营运资金；扩大产品候选药物的生产；应对竞争对手规模和性质的变化；招聘和留住关键高管和科学家；确保和维护与 Enveric 产品相关的法律权利，包括专利保护；识别并追求从其研发管道资产中获取价值的替代途径；继续作为持续经营的企业；以及有效管理其未来增长。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI4NDQ1NTByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI4NDQ1NTByMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212844550/en/</p>
<p>投资者关系</p>
<p>Tiberend Strategic Advisors, Inc.</p>
<p>David Irish</p>
<p>(231) 632-0002</p>
<p>dirish@tiberend.com</p>
<p>媒体关系</p>
<p>Tiberend Strategic Advisors, Inc.</p>
<p>Casey McDonald</p>
<p>(646) 577-8520</p>
<p>cmcdonald@tiberend.com</p>
<p>来源：Enveric Biosciences, Inc.</p>

ENVB

<p>Enveric Biosciences 宣布完成其认股权证的行使，筹集了 310 万美元的总收入。此次行使涉及 426,390 股，行使价格为每股 7.05 美元。新发行的未注册 E 系列和 F 系列认股权证的收益将用于产品开发和公司用途。H.C. Wainwright & Co. 担任了配售代理。新认股权证是在私募中提供的，并未根据 1933 年法案注册。Enveric 计划提交注册声明以便转售股份</p>

<p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, respectively, at a reduced exercise price of $7.05 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (No. 333-284277) and Form S-3 (No. 333-290580). The gross proceeds to the Company from the exercise of the warrants were approximately $3.1 million, prior to deducting placement agent fees and estimated offering expenses.</p>
<div class="lb-trans"><p>马萨诸塞州剑桥市 --（商业资讯）--Enveric Biosciences, Inc.（纳斯达克：ENVB）（“Enveric” 或 “公司”）是一家生物技术公司，致力于开发下一代神经可塑性小分子，以应对精神和神经疾病。今天，公司宣布已完成之前宣布的行使某些未到期认股权证的交易，购买总计 426,390 股，最初于 2025 年 2 月和 2025 年 9 月发行，行使价格分别为每股 36.00 美元和 10.98 美元，现以每股 7.05 美元的降低行使价格进行行使。根据有效的 S-1 表格（编号 333-284277）和 S-3 表格（编号 333-290580）注册声明，行使认股权证后可发行的普通股已注册。公司从行使认股权证中获得的总收益约为 310 万美元，未扣除承销商费用和预计的发行费用。</p>
</div><p>H.C. Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</p>
<div class="lb-trans"><p>H.C. Wainwright &amp; Co. 担任此次发行的独家承销商。</p>
</div><p>In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $106,597.50 in the aggregate, which are included in the gross proceeds to the Company), the Company issued new unregistered series E warrants to purchase up to 426,390 shares of common stock and new unregistered series F warrants to purchase up to 426,390 shares of common stock. The new series E warrants have an exercise price of $7.05 per share, are exercisable immediately and will expire five years after the effective date of the Resale Registration Statement (as defined below). The new series F warrants have an exercise price of $7.05 per share, are exercisable immediately and will expire eighteen months after the effective date of the Resale Registration Statement.</p>
<div class="lb-trans"><p>作为立即以现金行使认股权证的对价，并支付每个新未注册认股权证额外 0.125 美元（总计 106,597.50 美元，已包含在公司总收益中），公司发行了新的未注册 E 系列认股权证，购买最多 426,390 股普通股，以及新的未注册 F 系列认股权证，购买最多 426,390 股普通股。新的 E 系列认股权证的行使价格为每股 7.05 美元，可立即行使，并将在转售注册声明生效后五年到期。新的 F 系列认股权证的行使价格为每股 7.05 美元，可立即行使，并将在转售注册声明生效后十八个月到期。</p>
</div><p>The Company intends to use the net proceeds from the offering for product development, working capital and general corporate purposes.</p>
<div class="lb-trans"><p>公司计划将此次发行的净收益用于产品开发、营运资金和一般企业用途。</p>
</div><p>The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants (the “Resale Registration Statement”).</p>
<div class="lb-trans"><p>上述新认股权证是在适用的证券法 1933 年修正案（“1933 年法”）的注册要求豁免下进行的私募发行，并且与行使后可发行的普通股一起，尚未根据 1933 年法进行注册，且在未向证券交易委员会（“SEC”）注册或获得适用的豁免之前，不能在美国进行要约或销售。公司已同意向 SEC 提交一份注册声明，涵盖行使新认股权证后可发行的普通股的转售（“转售注册声明”）。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售或招揽购买此处描述的任何证券的要约，也不应在任何州或其他司法管辖区进行这些证券的销售，除非在任何此类州或其他司法管辖区的证券法下进行注册或资格认证。</p>
</div><p><strong>About Enveric Biosciences</strong></p>
<div class="lb-trans"><p><strong>关于 Enveric Biosciences</strong></p>
</div><p>Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.</p>
<div class="lb-trans"><p>Enveric Biosciences（纳斯达克：ENVB）是一家生物技术公司，专注于开发下一代小分子神经可塑性治疗药物，以满足精神和神经疾病的未满足需求。通过利用差异化的药物发现平台和不断增长的专利保护化学结构库，Enveric 正在推进一系列新型化合物的研发，旨在促进神经可塑性而不产生迷幻效果。Enveric 的主要候选药物 EB-003 是首个已知的化合物，旨在选择性地作用于 5-HT₂A 和 5-HT₁B 受体，具有快速、持久的抗抑郁和抗焦虑效果，并便于门诊使用。</p>
</div><p>For more information, please visit www.enveric.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.enveric.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management, including, but not limited to, statements regarding the anticipated use of proceeds from the offering. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.</p>
<div class="lb-trans"><p>本新闻稿包含适用证券法意义上的前瞻性陈述和前瞻性信息。这些陈述涉及未来事件或未来表现。除历史事实陈述外的所有陈述均可能是前瞻性陈述或信息。通常，前瞻性陈述和信息可以通过使用前瞻性术语来识别，例如 “计划”、“预期” 或 “未预期”、“提议”、“预算”、“探索”、“安排”、“寻求”、“估计”、“预测”、“打算”、“预期” 或 “未预期”，或 “相信”，或这些词语和短语的变体，或通过使用表明某些行动、事件或结果可能、能够、应该、会或可能发生或实现的词语或短语。前瞻性陈述可能包括关于未来的信念、计划、期望或意图的陈述，并基于管理层的信念以及管理层所做的假设和当前可用的信息，包括但不限于关于预期使用发行收益的陈述。实际结果可能因某些因素而与前瞻性陈述所设想的结果有重大差异，包括但不限于，Enveric 能否：最终确定并提交其 IND 申请给美国食品药品监督管理局；成功开展临床项目；实现技术发展所设想的价值创造；避免计划临床试验的延误；在临床前或临床试验中证明潜在产品的有效性或安全性；建立或维持治疗候选药物开发的合作关系；获得适当或必要的政府批准以市场潜在产品；以商业合理的条款获得未来产品开发和营运资金；扩大产品候选药物的生产；应对竞争对手规模和性质的变化；招聘和留住关键高管和科学家；确保和维护与 Enveric 产品相关的法律权利，包括专利保护；识别并追求从其研发管道资产中获取价值的替代途径；继续作为持续经营的企业；以及有效管理其未来增长。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI4NDQ1NTByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251212844550r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251212844550/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212844550/en/</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>Tiberend Strategic Advisors, Inc.</p>
<div class="lb-trans"><p>Tiberend Strategic Advisors, Inc.</p>
</div><p>David Irish</p>
<div class="lb-trans"><p>David Irish</p>
</div><p>(231) 632-0002</p>
<div class="lb-trans"><p>(231) 632-0002</p>
</div><p>dirish@tiberend.com</p>
<div class="lb-trans"><p>dirish@tiberend.com</p>
</div><p>Media Relations</p>
<div class="lb-trans"><p>媒体关系</p>
</div><p>Tiberend Strategic Advisors, Inc.</p>
<div class="lb-trans"><p>Tiberend Strategic Advisors, Inc.</p>
</div><p>Casey McDonald</p>
<div class="lb-trans"><p>Casey McDonald</p>
</div><p>(646) 577-8520</p>
<div class="lb-trans"><p>(646) 577-8520</p>
</div><p>cmcdonald@tiberend.com</p>
<div class="lb-trans"><p>cmcdonald@tiberend.com</p>
</div><p>Source: Enveric Biosciences, Inc.</p>
<div class="lb-trans"><p>来源：Enveric Biosciences, Inc.</p>
</div>

Enveric Biosciences 宣布完成认股权证的行使，获得 310 万美元的总收益 | ENVB 股票新闻